Cellectis SA (CLLS) FY2028Q4 Earning Prediction

05/12 04:00:00

After Hours

Cellectis SA (CLLS) is set to release its earnings performance on 05/12 04:00:00 in After Hours trading. Consensus forecasts predict a revenue of 13.83M and an earnings per share (EPS) of -0.23 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueMISS

13.83M

12.00M

-13.27%

EPSBEAT

-0.23

-0.18

+21.74%

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

CLLS Transcript

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Unknown8-5

The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Positive3-14

The earnings call reveals a strong financial position with significant investments from AstraZeneca and stable cash reserves. The Q&A section highlights confidence in upcoming data releases, suggesting positive future developments. The collaboration with AstraZeneca is fully reimbursed, reducing cash burn. Despite competitive pressures and supply chain challenges, the overall sentiment leans positive due to strategic partnerships and financial strength.

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Unknown11-5

The earnings call presents mixed signals. The AstraZeneca collaboration and strong cash position are positive indicators, but supply chain challenges and intense competition in cell and gene therapy pose risks. The Q&A reveals management's cautious approach to prioritizing projects and lack of clarity on future datasets. Additionally, deprioritizing UCART123 raises concerns. Despite these issues, the partnership with AstraZeneca provides a financial buffer, mitigating some negative impacts. Overall, the sentiment is neutral as positives balance out the negatives.

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Positive5-30

The earnings call reveals strong financial improvement, with a significant turnaround from a loss to a profit, which is a positive indicator. The collaboration with AstraZeneca and the potential for new programs provide further optimism. The Q&A section highlights ongoing developments and market expansion potential, especially in the EU. Although management avoided some specifics, the overall sentiment remains positive due to the financial recovery and strategic partnerships.

CLLS Report

Frequently Asked Questions

What is the Cellectis SA FY2028Q4 Earnings Release Date and Time?

Cellectis SA (CLLS) is scheduled to release its FY2028Q4 earnings report onMay 12, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Cellectis SA FY2028Q4 Revenue and EPS?

Analysts' consensus predicts 13.83M in revenue and an EPS of -0.23 for Cellectis SA's FY2028Q4.

What Does Intellectia's AI Predict for Cellectis SA FY2028Q4 Earnings?

Intellectia's exclusive AI algorithms forecast a forCellectis SA's FY2028Q4 earnings, with a prediction date of May 12, 2025. Cellectis SA

How Can I Use This Earnings Prediction to Trade CLLS Stock?

Leverage Intellectia's AI forecast to position trades ahead of theMay 12, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Cellectis SA FY2028Q4?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!